The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 11, 2022

Filed:

Oct. 21, 2019
Applicant:

Genentech, Inc., South San Francisco, CA (US);

Inventors:

Robert F. Kelley, Petaluma, CA (US);

Steven R. Leong, Berkeley, CA (US);

Wei-Ching Liang, Foster City, CA (US);

Mary Mathieu, San Francisco, CA (US);

Andrew G. Polson, San Francisco, CA (US);

Bing Zheng, Mountain View, CA (US);

Xiaocheng Chen, Foster City, CA (US);

Cecilia Pui Chi Chiu, San Carlos, CA (US);

Mark S. Dennis, San Carlos, CA (US);

Allen Ebens, San Carlos, CA (US);

Yan Wu, Foster City, CA (US);

Assignee:

Genentech, Inc., South San Francisco, CA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2851 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/57 (2013.01); C07K 2317/14 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/41 (2013.01); C07K 2317/52 (2013.01); C07K 2317/526 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/90 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01);
Abstract

The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.


Find Patent Forward Citations

Loading…